New study highlights risks of anti-ERBB2 cancer drugs during pregnancy

Study finds that anti-ERBB2 inhibitors used in breast cancer treatment pose significant risks to pregnancy and fetal health, including higher likelihoods of congenital defects and intrauterine growth restriction. Researchers recommend careful monitoring and possibly discontinuing these drugs during pregnancy despite their effectiveness against cancer.

Morning Rounds: Americans’ health is trending downward, poll finds

Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter here. Good morning. What do the numbers

December 15, 2023

Biocompatible liquid ink enables scalp-printed electrodes for non-invasive EEG

For the first time, scientists have invented a liquid ink that doctors can print onto a patient’s scalp to measure brain activity. The technology, presented

December 3, 2024

Cigarette smoke alters immune cell function in the lungs

Cigarette smoking is widespread and deadly, yet our understanding of how cigarette smoke actually causes serious respiratory illnesses is incomplete, which has severely hampered the

January 17, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.